Icon
+91 94997 68112
Login Register

Trileptal - (300mg/5ml; Oral suspension)

Oxcarbazepine Novartis
300mg/5ml; Oral suspension
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
More Than 5
More Than 5
Indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in pediatric patients aged 4 years and above with epilepsy, and as adjunctive therapy in pediatric patients aged 2 years and above with partial seizures.
Yes
***, ***** *** ****** ***** **** ** *** *** ***** ********* ******* ***** *********. ********* ** ******** ****** ** *** *****, ** *** *** **** ***********, *** *** ******** ******* ***. *****, ***** *** ****** ***** ******** *** ******* ** ******. **, *** ******'* *** **** *********** ** *********.
Trileptal Patent 1 Patent 2
*** ****** *** ********* *** *********
***** *** ********* *** *********
****** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ** ** *** ********* ******** *** ****** *** ****
***** ** \ ** ** *** ********* ******** ******** ** *** *, ****
****** ** \ ** ** *** ********* ******** ******** ** **** **, ****
  1. *** **, **** : *** ***** **** ** **** ****** '*** . ** *** ***** *********.
  2. *** **, **** : *** *** ***** ********.
  3. *** **, **** : ****** *** ******** *** ******** *******.
  4. *** *, **** : ***** *** ******** *** ******** *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.